Melanoma trials in Poland

In Poland 16 Also abroad 578

16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Not yet taking people in Poland
A Phase I/II trial to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JJP-1008 Alone or in Combination in Participants with Advanced Melanoma and Other Solid Tumors
Where
Gdansk, Skorzewo, Warsaw, Wroclaw
Age
18 years and over
People
30
Run by
JJP BIOLOGICS Sp. z o.o.
See details and how to join2026-527193-36-00 · EU 2026-527193-36-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Cracow
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Cracow, Lodz, Rzeszów, Siedlce, Skorzewo
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Gdansk, Gliwice, Konin, Siedlce, Warsaw
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 3Taking people
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Where
Lublin, Warsaw
Age
18 years to 70 years
People
670 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00
Phase 3Taking people
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Where
Cracow, Gdansk, Warsaw
Age
12 years and over
People
400 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06264180 · EU 2023-508612-29-00
Phase 3Taking people
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Where
Warsaw
Age
18 years and over
People
290 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT06246149 · EU 2023-510333-28-00
Phase 3Taking people
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
Where
Gdansk
Age
18 years and over
People
119 worldwide
Run by
Mabxience Research S.L.
See details and how to join2025-521562-95-00 · EU 2025-521562-95-00
Phase 3Taking people
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Where
Poznan, Warsaw
Age
18 years and over
People
520 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07015190 · EU 2025-522387-32-00
Phase 1Taking people
A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
Where
Gdansk
Age
18 years and over
People
83 worldwide
Run by
Celltrion Inc.
See details and how to join2023-510017-26-00 · EU 2023-510017-26-00
Phase 2/3Taking people
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Where
Warsaw
Age
18 years and over
People
280 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06581406 · EU 2023-508784-68-00
Phase 3Taking people
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Where
Bydgoszcz, Gdansk, Poznan, Warsaw
Age
18 years and over
People
540 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT05549297 · EU 2022-502732-39-00
Phase 3Taking people
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Where
Bydgoszcz, Gdansk, Skorzewo, Warsaw
Age
18 years and over
People
680 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT06112314
No phaseNot yet taking people in Poland
Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence
Where
Warsaw
Age
18 years and over
People
400
Run by
Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
See details and how to joinNCT07361666
Phase 4Taking people
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Where
Cracow, Gdansk, Warsaw
Age
18 years and over
People
50 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06887348 · EU 2025-521621-33-00
No phaseTaking people
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
Where
Gdansk, Warsaw
Age
18 years and over
People
200 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04498767